Renato Zambello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6606376/publications.pdf

Version: 2024-02-01

293	10,158	38742	48315
papers	citations	50 h-index	88 g-index

293	293	293	9237
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet, The, 2019, 394, 2096-2107.	13.7	435
2	Analysis of the receptor-ligand interactions in the natural killerâ€“mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood, 2005, 105, 2066-2073.	1.4	344
3	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood, 2008, 112, 3107-3114.	1.4	339
4	The Lymphoproliferative Disease of Granular Lymphocytes: Updated Criteria for Diagnosis. Blood, 1997, 89, 256-260.	1.4	324
5	Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood, 2012, 120, 9-19.	1.4	305
6	Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial. Journal of Clinical Oncology, 2011, 29, 986-993.	1.6	302
7	Autologous haematopoietic stem-cell transplantation versus bortezomibâ€“melphalanâ€“prednisone, with or without bortezomibâ€“lenalidomideâ€“dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematology,the, 2020, 7, e456-e468.	4.6	244
8	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. Journal of Clinical Oncology, 2014, 32, 634-640.	1.6	198
9	Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. Journal of Clinical Investigation, 2005, 115, 369-378.	8.2	192
10	Identification of NKp80, a novel triggering molecule expressed by human NK cells. European Journal of Immunology, 2001, 31, 233-242.	2.9	185
11	The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions. Cancer, 1987, 60, 2971-2978.	4.1	179
12	Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. Journal of Clinical Oncology, 2013, 31, 1442-1449.	1.6	167
13	Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. Cancer, 1990, 65, 341-348.	4.1	161
14	Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood, 2004, 104, 502-508.	1.4	144
15	The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. Journal of Clinical Investigation, 1999, 104, 115-121.	8.2	134
16	Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood, 2006, 108, 1698-1707.	1.4	123
17	Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 1705-1720.	10.7	120
18	Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. Journal of Clinical Investigation, 2005, 115, 369-378.	8.2	117

#	Article	IF	Citations
19	High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood, 1987, 70, 396-400.	1.4	109
20	Interleukin-15 Triggers the Proliferation and Cytotoxicity of Granular Lymphocytes in Patients With Lymphoproliferative Disease of Granular Lymphocytes. Blood, 1997, 89, 201-211.	1.4	106
21	Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood, 2003, 102, 1797-1805.	1.4	106
22	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematology,the, 2017, 4, e15-e23.	4.6	106
23	High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial. Journal of Clinical Oncology, 2015, 33, 3903-3910.	1.6	99
24	CXC Chemokines IP-10 and Mig Expression and Direct Migration of Pulmonary CD8 + /CXCR3 + T Cells in the Lungs of Patients with HIV Infection and T-Cell Alveolitis. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1466-1473.	5.6	95
25	Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. Blood, 1987, 70, 1530-1535.	1.4	95
26	High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood, 2002, 100, 1559-1565.	1.4	89
27	HIV-1 and the Lung: Infectivity, Pathogenic Mechanisms, and Cellular Immune Responses Taking Place in the Lower Respiratory Tract. The American Review of Respiratory Disease, 1993, 147, 1038-1049.	2.9	88
28	Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. Blood, 2013, 121, 3843-3854.	1.4	85
29	Interleukin-15 promotes the growth of leukemic cells of patients with B- cell chronic lymphoproliferative disorders. Blood, 1996, 87, 3327-3335.	1.4	81
30	Role for CXCR6 and Its Ligand CXCL16 in the Pathogenesis of T-Cell Alveolitis in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1290-1298.	5.6	81
31	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood, 2016, 127, 1102-1108.	1.4	78
32	LONG-TERM EFFECT OF RITUXIMAB IN ANTI-MAG POLYNEUROPATHY. Neurology, 2008, 71, 1742-1744.	1.1	75
33	Protein Kinase CK2 Inhibition Down Modulates the NF-ÎºB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells. PLoS ONE, 2013, 8, e75280.	2.5	75
34	Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia, 2014, 28, 1134-1136.	7.2	74
35	Phenotypical and Functional Analysis of Bronchoalveolar Lavage Lymphocytes in Patients with HIV Infection. The American Review of Respiratory Disease, 1988, 138, 1609-1615.	2.9	71
36	The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. Laboratory Investigation, 2012, 92, 1574-1582.	3.7	71

#	Article	IF	Citations
37	Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stressâ€“Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response. Clinical Cancer Research, 2012, 18, 1888-1900.	7.0	71
38	CD8+ T lymphocytes in the lung of acquired immunodeficiency syndrome patients harbor human immunodeficiency virus type 1. Blood, 1995, 85, 2308-2314.	1.4	67
39	STAT3 mutation impacts biological and clinical features of T-LGL leukemia. Oncotarget, 2017, 8, 61876-61889.	1.8	67
40	Clinical spectrum of Î³Î´+ T cell LGL leukemia: Analysis of 20 cases. Leukemia Research, 2008, 32, 45-48.	0.8	65
41	Spontaneous Production of Interleukin-6 by Alveolar Macrophages from Human Immunodeficiency Virus Type 1-Infected Patients. Journal of Infectious Diseases, 1992, 166, 731-737.	4.0	63
42	Expression of tumor necrosis factor-receptor superfamily members by lung T lymphocytes in interstitial lung disease.. American Journal of Respiratory and Critical Care Medicine, 1996, 153, 1359-1367.	5.6	63
43	Different Types of Cytotoxic Lymphocytes Recovered from the Lungs of Patients with Hypersensitivity Pneumonitis. The American Review of Respiratory Disease, 1988, 137, 70-74.	2.9	58
44	Phenotypic diversity of natural killer (NK) populations in patients with NK-type lymphoproliferative disease of granular lymphocytes. Blood, 1993, 81, 2381-2385.	1.4	55
45	Seroreactivity to an Envelope Protein of Human T-Cell Leukemia/Lymphoma Virus in Patients With CD3â¯ (Natural Killer) Lymphoproliferative Disease of Granular Lymphocytes. Blood, 1997, 90, 1977-1981.	1.4	55
46	Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia, 2011, 25, 1768-1781.	7.2	55
47	Protein kinase CK2 regulates AKT, NF-ÎºB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia. Leukemia, 2017, 31, 292-300.	7.2	55
48	Longitudinal study of alveolitis in hypersensitivity pneumonitis patients: An immunologic evaluation. Journal of Allergy and Clinical Immunology, 1988, 82, 577-585.	2.9	54
49	Demonstration of Chlamydia pneumoniae in atherosclerotic arteries from various vascular regions. Atherosclerosis, 2001, 158, 73-79.	0.8	54
50	MATRixâ€“RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematology,the, 2021, 8, e110-e121.	4.6	54
51	Rituximab-responsive CIDP. European Journal of Neurology, 2004, 11, 788-788.	3.3	53
52	Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. Blood, 2008, 112, 4665-4674.	1.4	53
53	Alveolar Macrophages from Patients with AIDS and AIDS-related Complex Constitutively Synthesize and Release Tumor Necrosis Factor Alpha. The American Review of Respiratory Disease, 1991, 144, 195-201.	2.9	51
54	Interleukin-15 Triggers Activation and Growth of the CD8 T-Cell Pool in Extravascular Tissues of Patients With Acquired Immunodeficiency Syndrome. Blood, 1997, 90, 1115-1123.	1.4	51

#	Article	IF	Citations
55	Complex karyotype, older age, and reduced firstâ€line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with longâ€term followâ€up. American Journal of Hematology, 2015, 90, 515-523.	4.1	51
56	Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood, 1994, 84, 4249-4256.	1.4	50
57	Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients. Annals of Oncology, 2014, 25, 2030-2035.	1.2	49
58	Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients. Leukemia, 2020, 34, 1116-1124.	7.2	49
59	Primary Mediastinal Large B-Cell Lymphoma: Results of Intensive Chemotherapy Regimens (MACOP-B/VACOP-B) Plus Involved Field Radiotherapy on 53 Patients. A Single Institution Experience. International Journal of Radiation Oncology Biology Physics, 2007, 68, 823-829.	0.8	48
60	Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. Haematologica, 2015, 100, e515-e518.	3.5	48
61	CD8 alveolitis in sarcoidosis: Incidence, phenotypic characteristics, and clinical features. American Journal of Medicine, 1993, 95, 466-472.	1.5	46
62	Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity. Journal of Hematology and Oncology, 2013, 6, 78.	17.0	46
63	Activated T Cells with Immunoregulatory Functions at Different Sites of Involvement in Sarcoidosis.. Annals of the New York Academy of Sciences, 1986, 465, 56-73.	3.8	45
64	Failure to detect Epstein-Barr virus DNA in peripheral blood mononuclear cells of most patients with large granular lymphocyte leukemia. Blood, 1993, 81, 2723-2727.	1.4	45
65	Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. British Journal of Haematology, 2007, 138, 594-602.	2.5	44
66	Expression and role of CCR6/CCL20 chemokine axis in pulmonary sarcoidosis. Journal of Leukocyte Biology, 2007, 82, 946-955.	3.3	43
67	Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission. British Journal of Cancer, 1988, 58, 368-372.	6.4	42
68	Prognostic Significance of the Evaluation of Bronchoalveolar Lavage Cell Populations in Patients with HIV-1 Infection and Pulmonary Involvement. Chest, 1991, 100, 1601-1606.	0.8	41
69	Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes. Leukemia, 2007, 21, 1060-1069.	7.2	40
70	Insights Into Genetic Landscape of Large Granular Lymphocyte Leukemia. Frontiers in Oncology, 2020, 10, 152.	2.8	40
71	Interleukin-15: A Novel Cytokine with Regulatory Properties on Normal and Neoplastic B Lymphocytes. Leukemia and Lymphoma, 1997, 27, 35-42.	1.3	39
72	Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. BMC Cancer, 2010, 10, 526.	2.6	39

#	Article	IF	Citations
73	Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. Oncotarget, 2015, 6, 42130-42149.	1.8	39
74	NKG2A inhibits NKG2C effector functions of Î³Î´ T cells: implications in health and disease. Journal of Leukocyte Biology, 2010, 89, 75-84.	3.3	38
75	Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma. Clinical Radiology, 2017, 72, 850-857.	1.1	38
76	Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higherâ€risk myelodysplastic syndromes or chronic myelomonocytic leukemia. European Journal of Haematology, 2013, 90, 345-348.	2.2	37
77	T cell large granular lymphocyte leukemia and chronic NK lymphocytosis. Best Practice and Research in Clinical Haematology, 2019, 32, 207-216.	1.7	37
78	Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial. Blood, 2020, 136, 35-37.	1.4	37
79	Pulmonary alveolar macrophages in patients with sarcoidosis and hypersensitivity pneumonitis: Characterization by monoclonal antibodies. Journal of Clinical Immunology, 1987, 7, 64-70.	3.8	36
80	Clinicopathological features of aggressive large granular lymphocyte leukaemia resemble Fas ligand transgenic mice. British Journal of Haematology, 2000, 108, 717-723.	2.5	36
81	Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches. Haematologica, 2009, 94, 1341-1345.	3.5	36
82	Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clinical Rheumatology, 2015, 34, 1571-1580.	2.2	36
83	Mechanisms accounting for the defective natural killer activity in patients with hairy cell leukemia. Blood, 1990, 75, 1525-1530.	1.4	35
84	Hepatitis B virus binds to peripheral blood mononuclear cells via the pre S1 protein. Journal of Hepatology, 1991, 12, 203-206.	3.7	35
85	Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 277, L240-L250.	2.9	35
86	Natural killer receptors in patients with lymphoproliferative diseases of granular lymphocytes. Seminars in Hematology, 2003, 40, 201-212.	3.4	35
87	Cell membrane expression and functional role of the p75 subunit of interleukin-2 receptor in lymphoproliferative disease of granular lymphocytes. Blood, 1990, 76, 2080-2085.	1.4	34
88	HIV and pulmonary immune responses. Trends in Immunology, 1996, 17, 359-364.	7.5	34
89	Selection of T lymphocytes bearing limited TCR-Vbeta regions in the lung of hypersensitivity pneumonitis and sarcoidosis.. American Journal of Respiratory and Critical Care Medicine, 1997, 155, 587-596.	5.6	34
90	Cortactin, another player in the Lyn signaling pathway, is over-expressed and alternatively spliced in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Haematologica, 2014, 99, 1069-1077.	3.5	32

#	Article	IF	Citations
91	The natural killer-related receptor for HLA-C expressed on T cells from CD3+ lymphoproliferative disease of granular lymphocytes displays either inhibitory or stimulatory function. Blood, 1996, 87, 2369-2375.	1.4	31
92	Lenalidomide long-term neurotoxicity. Neurology, 2016, 87, 1161-1166.	1.1	31
93	Phenotypic and functional analyses of dendritic cells in patients with lymphoproliferative disease of granular lymphocytes (LDGL). Blood, 2005, 106, 3926-3931.	1.4	30
94	Bendamustine salvage therapy for T cell neoplasms. Annals of Hematology, 2013, 92, 1249-1254.	1.8	30
95	Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. Leukemia and Lymphoma, 2016, 57, 1823-1830.	1.3	30
96	Inactivation of CK1Î± in multiple myeloma empowers drug cytotoxicity by affecting AKT and Î²-catenin survival signaling pathways. Oncotarget, 2017, 8, 14604-14619.	1.8	30
97	HS1, a Lyn Kinase Substrate, Is Abnormally Expressed in B-Chronic Lymphocytic Leukemia and Correlates with Response to Fludarabine-Based Regimen. PLoS ONE, 2012, 7, e39902.	2.5	29
98	Ex Vivo Signaling Protein Mapping in T Lymphocytes in the Psoriatic Arthritis Joints. Journal of rheumatology Supplement, The, 2015, 93, 48-52.	2.2	29
99	Pulmonary alveolar macrophages from patients with active sarcoidosis express type IV collagenolytic proteinase. An enzymatic mechanism for influx of mononuclear phagocytes at sites of disease activity.. Journal of Clinical Investigation, 1989, 84, 605-612.	8.2	29
100	High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 3120-3131.	1.6	29
101	Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. Lancet Haematology,the, 2017, 4, e137-e146.	4.6	28
102	IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1094-1097.	1.9	28
103	Identification of a miR-146b-Fas ligand axis in the development of neutropenia in T large granular lymphocyte leukemia. Haematologica, 2020, 105, 1351-1360.	3.5	28
104	Increased levels of soluble CD8 molecule in the serum of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related disorders. Clinical Immunology and Immunopathology, 1989, 50, 146-153.	2.0	27
105	Î³Î´ T Cell Receptor Subsets in the Lung of Patients with HIV-1 Infection. Cellular Immunology, 1994, 153, 194-205.	3.0	27
106	NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias. Cells, 2020, 9, 768.	4.1	27
107	CXCR3/CXCL10 interactions in the development of hypersensitivity pneumonitis. Respiratory Research, 2005, 6, 20.	3.6	26
108	Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and <scp>L</scp>yn inhibition by nocodazole. British Journal of Haematology, 2014, 165, 659-672.	2.5	26

#	Article	IF	Citations
109	Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 612-620.e5.	0.4	26
110	Immunologic abnormalities in angioimmunoblastic lymphadenopathy. Cancer, 1987, 60, 2412-2418.	4.1	25
111	Impaired cytokine production by neutrophils isolated from patients with AIDS. Aids, 1998, 12, 373-379.	2.2	25
112	CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cellsâ€“T-Cell Interaction. Blood, 1999, 93, 1277-1286.	1.4	25
113	Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkinâ€™s lymphoma: evidence from a multicenter, retrospective study. Annals of Hematology, 2016, 95, 1107-1114.	1.8	25
114	Lack of expression of inhibitory KIR3DL1 receptor in patients with natural killer cell-type lymphoproliferative disease of granular lymphocytes. Haematologica, 2010, 95, 1722-1729.	3.5	24
115	Pachymeningeal involvement in POEMS syndrome: MRI and histopathological study. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 33-37.	1.9	24
116	Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective caseâ€matched study. American Journal of Hematology, 2014, 89, 355-362.	4.1	24
117	B7 costimulatory molecules from malignant cells in patients with B-cell chronic lymphoproliferative disorders trigger T-cell proliferation. Cancer, 2000, 89, 1259-1268.	4.1	23
118	State of the art in natural killer cell malignancies. International Journal of Laboratory Hematology, 2012, 34, 117-128.	1.3	23
119	Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia. Nature Communications, 2022, 13, 1981.	12.8	23
120	Cytotoxic Events Taking Place in the Lung of Patients with HIV-1 Infection: Evidence of an Intrinsic Defect of the Major Histocompatibility Complex-unrestricted Killing Partially Restored by the Incubation with rIL-2. The American Review of Respiratory Disease, 1990, 142, 516-522.	2.9	22
121	Activating KIRs in Chronic Lymphoproliferative Disorder of NK Cells: Protection from Viruses and Disease Induction?. Frontiers in Immunology, 2014, 5, 72.	4.8	22
122	Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma. Cell Death Discovery, 2019, 5, 98.	4.7	22
123	A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells. Blood Cancer Journal, 2020, 10, 42.	6.2	22
124	Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients.. Journal of Clinical Oncology, 2021, 39, 8002-8002.	1.6	22
125	Skewing of the T-cell receptor repertoire in the lung of patients with HIV-1 infection. Aids, 1996, 10, 729-738.	2.2	21
126	Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells. Haematologica, 2014, 99, 1826-1833.	3.5	21

#	Article	IF	Citations
127	HTLV-I ANTIBODIES AND LYMPHOPROLIFERATIVE DISEASE OF GRANULAR LYMPHOCYTES. Lancet, The, 1987, 330, 1527.	13.7	20
128	Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation. Blood Cancer Journal, 2018, 8, 51.	6.2	20
129	Phenotypical and functional analysis of natural killer cells in sarcoidosis. Clinical Immunology and Immunopathology, 1985, 37, 262-275.	2.0	19
130	Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes. Blood, 2000, 96, 647-654.	1.4	19
131	Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia. Hematological Oncology, 2017, 35, 925-928.	1.7	19
132	The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. Blood Cancer Journal, 2018, 8, 20.	6.2	19
133	Role of tumor necrosis factor-alpha and its specific 55-Kd and 75-Kd receptors in patients with lymphoproliferative disease of granular lymphocytes. Blood, 1992, 80, 2030-2037.	1.4	18
134	Lenalidomide in patients with chemotherapyâ€induced polyneuropathy and relapsed or refractory multiple myeloma: results from a singleâ€centre prospective study. Journal of the Peripheral Nervous System, 2013, 18, 19-24.	3.1	18
135	A Pyrazolo[3,4-‹i›d‹/i›]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. Oncotarget, 2016, 7, 65171-65184.	1.8	18
136	The interleukin-2/interleukin-2 receptor system: structural, immunological, and clinical features. International Journal of Clinical and Laboratory Research, 1992, 22, 133-142.	1.0	17
137	Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor. British Journal of Cancer, 1995, 71, 240-245.	6.4	17
138	Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. Leukemia Research, 2006, 30, 283-285.	0.8	17
139	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. Haematologica, 2020, 106, 291-294.	3.5	17
140	A Phase III Study of Enoxaparin Versus Low-Dose Warfarin Versus Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated up-Front with Thalidomide-Containing Regimens. Blood, 2008, 112, 3017-3017.	1.4	17
141	Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission. Cancer, 1989, 64, 667-672.	4.1	16
142	Detection of Epstein-Barr Virus by PCR Analyses in Lymphoproliferative Disease of Granular Lymphocytes. Leukemia and Lymphoma, 1996, 23, 371-374.	1.3	16
143	Detection of Chlamydophila pneumoniae DNA in peripheral blood mononuclear cells of blood donors in the north-east of Italy. Medical Microbiology and Immunology, 2001, 190, 139-144.	4.8	16
144	Primary Cutaneous Mantle Cell Lymphoma. Acta Dermato-Venereologica, 2011, 91, 474-475.	1.3	16

#	Article	IF	Citations
145	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. Haematologica, 2020, 105, 1074-1080.	3.5	16
146	Chimerism Monitoring Techniques after Hematopoietic Stem Cell Transplantation: An Overview of the Last 15 Years of Innovations. Diagnostics, 2021, 11, 621.	2.6	16
147	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. Blood, 2020, 136, 37-38.	1.4	16
148	Neutropenia and Large Granular Lymphocyte Leukemia: From Pathogenesis to Therapeutic Options. Cells, 2021, 10, 2800.	4.1	16
149	Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytes. Cancer, 1989, 64, 2019-2023.	4.1	15
150	Shedding of the soluble form of the CD8 complex by CD8 +/HLA-DR + cells in HIV-1-infected patients. Aids, 1991, 5, 813-820.	2.2	15
151	Antiapoptotic Effects of IL-15 on Pulmonary Tc1 Cells of Patients with Human Immunodeficiency Virus Infection. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 484-489.	5.6	15
152	T cells in the lung of patients with hypersensitivity pneumonitis accumulate in a clonal manner. Journal of Leukocyte Biology, 2004, 75, 798-804.	3.3	15
153	Analysis of NK cell/DC interaction in NK-type lymphoproliferative disease of granular lymphocytes (LDGL): role of DNAM-1 and NKp30. Experimental Hematology, 2009, 37, 1167-1175.	0.4	15
154	Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia. Annals of Hematology, 2017, 96, 159-161.	1.8	15
155	Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients. Blood, 2019, 134, 4322-4322.	1.4	15
156	Identification of novel STAT5B mutations and characterization of TCRÎ² signatures in CD4+ T-cell large granular lymphocyte leukemia. Blood Cancer Journal, 2022, 12, 31.	6.2	15
157	Spontaneous resolution of p58/EB6 antigen restricted NKâ€type lymphoproliferative disease of granular lymphocytes: role of Epstein Barr virus infection. British Journal of Haematology, 1997, 99, 215-221.	2.5	14
158	T-cell type lymphoproliferative disease of granular lymphocytes (LDGL) is equipped with a phenotypic pattern typical of effector cytotoxic cells. Leukemia Research, 2007, 31, 371-377.	0.8	14
159	Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2. Leukemia, 2014, 28, 2094-2097.	7.2	14
160	Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis. Blood Cancer Journal, 2020, 10, 18.	6.2	14
161	Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder really two distinct diseases?. Translational Medicine @ UniSa, 2014, 8, 4-11.	0.5	14
162	Alpha-interferon activated cytotoxic lymphocytes in hairy cell leukemia patients: Evaluation of cytotoxic events. Leukemia Research, 1987, 11, 843-847.	0.8	13

#	Article	IF	Citations
163	Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy. Clinical Neurophysiology, 2011, 122, 2518-2522.	1.5	13
164	Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI. Annals of Hematology, 2019, 98, 679-689.	1.8	13
165	A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients. Blood, 2013, 122, 536-536.	1.4	13
166	Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2017, 35, 8003-8003.	1.6	13
167	Highly concentrated urine-purified Tac peptide fails to inhibit IL-2-dependent cell proliferation in vitro. Cellular Immunology, 1992, 141, 253-259.	3.0	12
168	Functional role of IL-2 receptors on tumour-infiltrating lymphocytes. British Journal of Cancer, 1994, 69, 1046-1051.	6.4	12
169	Pachymeningeal involvement in POEMS syndrome: Dramatic cerebral MRI improvement after lenalidomide therapy. American Journal of Hematology, 2012, 87, 539-541.	4.1	12
170	KIR/HLAâ€ mismatching and risk of relapse in paediatric patients undergoing nonâ€haploidentical allogeneic haematopoietic stem cell transplantation. Pediatric Transplantation, 2011, 15, 198-204.	1.0	11
171	Neurolymphomatosis, a rare manifestation of peripheral nerve involvement in lymphomas: Suggestive features and diagnostic challenges. Journal of the Peripheral Nervous System, 2020, 25, 312-315.	3.1	11
172	CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cellsâ€“T-Cell Interaction. Blood, 1999, 93, 1277-1286.	1.4	11
173	Clonally expanded CD3+, CD4â^', CD8â^' cells bearing the or the T-cell receptor in patients with the lymphoproliferative disease of granular lymphocytes. Clinical Immunology and Immunopathology, 1991, 60, 371-383.	2.0	10
174	Alveolar Macrophages in HIV-1 Infection Express Accessory Molecules, Activation Markers, and Release Increased Biological Response Modifiers. Chest, 1993, 103, 108S-111S.	0.8	10
175	The Italian quality control study for evaluation of CD4 cells in centres involved in the treatment of HIV-1 patients. Clinical and Experimental Immunology, 1998, 111, 564-573.	2.6	10
176	Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies. PLoS ONE, 2021, 16, e0247717.	2.5	10
177	Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes. Blood, 2018, 132, 125-125.	1.4	10
178	Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors. Blood, 2010, 116, 620-620.	1.4	10
179	Expression of a functional p75 interleukin-2 receptor on lung lymphocytes from patients with human immunodeficiency virus type 1 (HIV-1) infection. Journal of Clinical Immunology, 1992, 12, 371-380.	3.8	9
180	Phenotypic and functional characterization of cytotoxic cells derived from endomyocardial biopsies in human cardiac allografts. Cellular Immunology, 1992, 141, 332-341.	3.0	9

#	Article	IF	Citations
181	ILâ€12 is involved in the activation of CD3 + granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. British Journal of Haematology, 1996, 92, 308-314.	2.5	9
182	Upregulation of CXCR1 by proliferating cells in patients with lymphoproliferative disease of granular lymphocytes. British Journal of Haematology, 2003, 120, 765-773.	2.5	9
183	Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicineâ€"Results from the Italian â€˜Back to Lifeâ€™ project. Quality of Life Research, 2018, 27, 1545-1554.	3.1	9
184	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 533-540.	0.4	9
185	Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. Blood Cancer Journal, 2020, 10, 58.	6.2	9
186	Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience. Leukemia, 2022, 36, 1947-1950.	7.2	9
187	Rearrangement for the T-cell receptor gene and co-expression of immature T-cell markers and natural killer cell phenotype, in a patient with acute lymphoblastic leukaemia. British Journal of Haematology, 1987, 65, 17-22.	2.5	8
188	Lymphoproliferative disease of granular lymphocytes in a patient with concomitant hepatitis B virus infection of CD4 lymphocytes. Journal of Clinical Immunology, 1989, 9, 401-408.	3.8	8
189	Improvement of peripheral nervous system manifestations of Bâ€cell nonâ€Hodgkin's lymphoma after rituximab therapy. Journal of the Peripheral Nervous System, 2009, 14, 146-148.	3.1	8
190	Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse. British Journal of Haematology, 2020, 188, 907-917.	2.5	8
191	Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf. Pharmaceuticals, 2021, 14, 40.	3.8	8
192	MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial. Blood, 2019, 134, 4321-4321.	1.4	8
193	T lymphocytes with Î³/Î´ T-cell receptors in patients with AIDS and Pneumocystis carinii pneumonia. Aids, 1995, 9, 203-204.	2.2	7
194	Bendamustine in relapsed/refractory multiple myeloma: the â€œreal-lifeâ€•side of the moon. Leukemia and Lymphoma, 2015, 56, 1510-1513.	1.3	7
195	Longâ€lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large Bâ€cell lymphoma who are not eligible for or failed autologous transplantation. Hematological Oncology, 2020, 38, 257-265.	1.7	7
196	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. Blood Cancer Journal, 2021, 11, 73.	6.2	7
197	Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes. Blood, 2000, 96, 647-654.	1.4	7
198	Defining TCRÎ³Î´ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation. Nature Communications, 2022, 13, .	12.8	7

#	Article	IF	Citations
199	Release of natural killer cytotoxic factor in patients with lymphoproliferative disease of granular lymphocytes. Leukemia Research, 1989, 13, 315-322.	0.8	6
200	Cytotoxic In vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy effects of activation with recombinant interleukin-2. Cancer, 1992, 69, 2525-2531.	4.1	6
201	Cellular Immunity in Sarcoidosis and Hypersensitivity Pneumonitis. Chest, 1993, 103, 139S-143S.	0.8	6
202	Persistent polyclonal lymphocytosis in human immunodeficiency virus-1- infected patients. Blood, 1993, 81, 3015-3021.	1.4	6
203	Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells. Cancer, 1994, 74, 2562-2569.	4.1	6
204	Childhood onset cyclic neutropenia: Gâ€€CSF therapy restores neutrophil count but does not influence superoxide anion and cytokine release by neutrophils. British Journal of Haematology, 1995, 89, 277-281.	2.5	6
205	Lysis of pulmonary fibroblasts by lymphokine (ILâ€2)â€activated killer cellsâ€"a mechanism affecting the human lung microenvironment?. Clinical and Experimental Immunology, 1996, 105, 383-388.	2.6	6
206	Detection of identical T-cell clonotype expansions in both the donor and recipient after allogeneic bone marrow transplantation. British Journal of Haematology, 1999, 106, 119-127.	2.5	6
207	Lenalidomide for bortezomib-resistant multiple myeloma. Nature Reviews Clinical Oncology, 2010, 7, 1-1.	27.6	6
208	Persistent Improvement In Clinical Outcomes With Bortezomib-Thalidomide-Dexamethasone Vs Thalidomide-Dexamethasone Incorporated Into Double Autologous Transplantation For Multiple Myeloma: An Updated Analysis Of Phase 3 Gimema-MMY-3006 Study. Blood, 2013, 122, 2090-2090.	1.4	6
209	Epidemiology and Risk Factors of Invasive Fungal Infections Among 795 Patients with Chronic Lymphocytic Leukemia from the Padua University. Blood, 2016, 128, 2527-2527.	1.4	6
210	Interrogating molecular genetics to refine LGLL classification. Blood, 2022, 139, 3002-3004.	1.4	6
211	Cytotoxic Lymphocytes in the Lungs of Patients with Hypersensitivity Pneumonitis.. Annals of the New York Academy of Sciences, 1988, 532, 447-450.	3.8	5
212	Serum levels of soluble CD8 are increased in patients with B chronic lymphocytic leukemia. European Journal of Cancer & Clinical Oncology, 1989, 25, 1577-1581.	0.7	5
213	Phenotypical and functional evaluation of CD8+/S6F1+ T lymphocytes in haemophiliac individuals with HIV-1 infection. Clinical and Experimental Immunology, 2008, 93, 51-55.	2.6	5
214	Cardio-vascular Toxicity in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients Treated With Carfilzomib, Cyclophosphamide and Dexamethasone: Results From an Integrated Analysis of 3 Phase I/II Trials. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e7.	0.4	5
215	Phase <scp>II</scp> trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib. British Journal of Haematology, 2019, 185, 944-947.	2.5	5
216	Large Granular Lymphocyte Leukemia and Precapillary Pulmonary Hypertension. Chest, 2020, 158, 2602-2609.	0.8	5

#	Article	IF	Citations
217	Superior Efficacy of VTD over VCD As Induction Therapy for Autotransplantation-Eligible, Newly Diagnosed, Myeloma Patients. Blood, 2014, 124, 197-197.	1.4	5
218	Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study. Blood, 2014, 124, 2110-2110.	1.4	5
219	Rituximab, Bendamustine and Cytarabine (R-BAC) Is a Very Active Regimen In Patients with Mantle Cell Lymphoma Not Eligible for Intensive Chemotherapy or Autologous Transplant. Blood, 2011, 118, 2677-2677.	1.4	5
220	Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. Blood Cancer Journal, 2021, 11, 197.	6.2	5
221	NK cells and their receptors in naive and rituximab-treated patients with anti-MAG polyneuropathy. Journal of the Neurological Sciences, 2013, 331, 86-89.	0.6	4
222	Superior Complete Response Rate (CR) and Progression-Free Survival (PFS) with Bortezomib-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) As Consolidation Therapy After Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM). Blood, 2011, 118, 1871-1871.	1.4	4
223	Comparative Analysis of NK Receptor and T-Cell Receptor Repertoires in Patients with Chronic Myeloid Leukemia Treated with Different Tyrosine Kinase Inhibitors. Blood, 2014, 124, 5508-5508.	1.4	4
224	Protein Kinase CK1Î± Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma. Frontiers in Oncology, 2021, 11, 733848.	2.8	4
225	Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel. Blood, 2020, 136, 38-39.	1.4	4
226	B-ly-7, a monoclonal antibody labeling of activated lung lymphocytes [letter]. Blood, 1991, 77, 1855-1856.	1.4	3
227	The raft marker GM1 identifies functional subsets of granular lymphocytes in patients with CD3+ lymphoproliferative disease of granular lymphocytes. Leukemia, 2004, 18, 771-776.	7.2	3
228	Psoriasis induced by thalidomide in a patient with multiple myeloma. BMJ Case Reports, 2014, 2014, bcr2014204469-bcr2014204469.	0.5	3
229	Severe infections unrelated to neutropenia impact on overall survival in multiple myeloma patients: results of a single centre cohort study. British Journal of Haematology, 2019, 186, e13-e17.	2.5	3
230	Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From â€œOmicsâ€•Research. Frontiers in Oncology, 2020, 10, 802.	2.8	3
231	Lack of Viral Load Within Chronic Lymphoproliferative Disorder of Natural Killer Cells: What Is Outside the Leukemic Clone?. Frontiers in Oncology, 2020, 10, 613570.	2.8	3
232	The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients. Dentistry Journal, 2021, 9, 11.	2.3	3
233	Overall Safety and Treatment Duration in Lenalidomide (LEN)-, Thalidomide (THAL)-, and Bortezomib (BORT)-Treated Patients (Pts) within the European Post-Approval Safety Study (EU PASS) of Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2012, 120, 4068-4068.	1.4	3
234	Rituximab-Bendamustine Cytarabine (R-BAC) As Frontline Therapy in Mantle Cell Lymphoma: A Single-Center Experience. Blood, 2015, 126, 2710-2710.	1.4	3

#	Article	IF	Citations
235	Interleukin-15 Triggers Activation and Growth of the CD8 T-Cell Pool in Extravascular Tissues of Patients With Acquired Immunodeficiency Syndrome. Blood, 1997, 90, 1115-1123.	1.4	3
236	Impact of Imaging FDG-PET/CT Minimal Residual Disease Assessment on Outcomes and Matching with Bone Marrow Techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results of the Phase II Randomized Forte Trial. Blood, 2020, 136, 27-28.	1.4	3
237	Alpha-interferon activates the natural killer system in patients with hairy cell leukemia. Blood, 1986, 68, 293-296.	1.4	3
238	Hairy cell sensitivity to the lysis in vitro. Cancer Immunology, Immunotherapy, 1989, 30, 254-256.	4.2	2
239	Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 592-598.	0.4	2
240	Steroid-responsive hyperammonemic encephalopathy as first manifestation of multiple myeloma. Neurological Sciences, 2017, 38, 503-505.	1.9	2
241	Atypical Mature T-Cell Neoplasms: The Relevance of the Role of Flow Cytometry . OncoTargets and Therapy, 2020, Volume 13, 7605-7614.	2.0	2
242	Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. Cancer, 2021, 127, 2015-2024.	4.1	2
243	Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients. Frontiers in Oncology, 2021, 11, 682658.	2.8	2
244	Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial. Blood, 2019, 134, 353-353.	1.4	2
245	Multiple Myeloma Cells Survival and Proliferation Rely on High Levels and Activity of the Serine-Threonine Kinase CK2.. Blood, 2004, 104, 643-643.	1.4	2
246	Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi. Blood, 2016, 128, 472-472.	1.4	2
247	Predictor of the Rate of CD4 Lymphocyte Loss in HIV-1-Seropositive Asymptomatic Hemophiliacs byin VitroImmunoglobulin Synthesis. Clinical Immunology and Immunopathology, 1996, 81, 224-228.	2.0	1
248	Bortezomib-Thalidomide-Dexamethasone Incorporated Into Autotransplantation Is Associated with More Favorable Outcomes After Relapse in Comparison with Thalidomide-Dexamethasone Plus Autotransplantation in Multiple Myeloma. Blood, 2012, 120, 4210-4210.	1.4	1
249	High Doses of Antimetabolites Followed By High-Dose Sequential Chemoimmunotherapy and Autologous Stem Cell Transplant in Patients with Systemic B-Cell Lymphoma and Secondary Central Nervous System Involvement: Final Results of a Multicenter Phase II Trial. Blood, 2014, 124, 1724-1724.	1.4	1
250	A Pyrazolo[3,4-d]Pyrimidine Compound Reduces Fyn Phosphorylation and Induces Apoptosis in Large Granular Lymphocyte Leukemia Cells. Blood, 2015, 126, 3254-3254.	1.4	1
251	Phenotypic Heterogeneity of Chronic Lymphoproliferative Disorder of NK Cells. Blood, 2015, 126, 3876-3876.	1.4	1
252	Role of Protein Kinase CK2 in the Retinoic Acid-Induced Differentiation of Acute Promyelocytic Leukemia Cells.. Blood, 2007, 110, 879-879.	1.4	1

#	Article	IF	Citations
253	Lenalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) in Patients with Chemosensitive Relapse of Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT) or Experienced Relapse after Transplantation: Results of a Multicentre Phase II Trial. Blood, 2015, 126, 1547-1547.	1.4	1
254	Lenalidomide Maintenance Significantly Improves Survival Figures in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Final Results of a Multicentre Phase II Trial. Blood, 2016, 128, 474-474.	1.4	1
255	Synergistic Role of Leukemic and Non-Leukemic Immune Repertoires in CD8+ T-Cell Large Granular Lymphocytic Leukemia As Identified By Single-Cell Transcriptomics. Blood, 2021, 138, 1318-1318.	1.4	1
256	Inhibition of CTLI-line lysis after gangliosides treatment. Pharmacological Research, 1992, 26, 190-191.	7.1	0
257	In vitro immunoglobulin synthesis as a CD4+ lymphocyte depletion predictor in HIV-1-infected asymptomatic haemophiliacs. Aids, 1994, 8, 1728-1729.	2.2	0
258	Aggressive LGL leukaemia presentation in old age. Annals of Hematology, 2011, 90, 603-606.	1.8	0
259	Infections in Multiple Myeloma: An Understimate Risk Factor of Comorbidity. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e30.	0.4	0
260	Hyperammonemic Encephalopathy as Initial Presentation of Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e102-e103.	0.4	0
261	Diffusion Weighted Whole Body MRI for Evaluation of Early Response in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e118.	0.4	0
262	Immune Profiling of Plasma Cell Dyscrasias Reveals a Therapy Related T-Cell Modulation in Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e87.	0.4	0
263	Maintenance Therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II, Randomized Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e271.	0.4	0
264	Large Granular Lymphocyte Leukemia. Hematologic Malignancies, 2021, , 231-246.	0.2	0
265	Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo).. Blood, 2004, 104, 903-903.	1.4	0
266	Role of Hematopoietic-Specific Protein 1 (HS1) in Apoptosis in B-Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2809-2809.	1.4	0
267	Effects of CK2 Inhibition on Multiple Signaling Pathways in Myeloma Cells. Blood, 2008, 112, 5163-5163.	1.4	0
268	Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments In Patients with Relapsed or Refractory Multiple Myeloma: Evaluation of Peripheral Neuropathy In the First 1,011 Patients. Blood, 2010, 116, 1939-1939.	1.4	0
269	Cortactin Is Overexpressed In Neoplastic Cells of Patients with B-Cell Chronic Lymphocytic Leukemia. Blood, 2010, 116, 2436-2436.	1.4	0
270	Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2011, 118, 1867-1867.	1.4	0

#	Article	IF	Citations
271	Intrinsic and Estrinsic Mechanism Contributes to Maintain the JAK/STAT Pathway Aberrantly Activated in T-Type Large Granular Lymphocyte Leukemia. Blood, 2011, 118, 1375-1375.	1.4	0
272	Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients.. Blood, 2012, 120, 2971-2971.	1.4	0
273	Bendamustine Salvage Therapy for T-Cell Non Hodgkin Lymphoma. Blood, 2012, 120, 4860-4860.	1.4	0
274	T Large Granular Lymphocytes Leukemia (T-LGLL) and Natural Killer Chronic Lymphoproliferative Disorder (NK-CLPD): Two Diseases With a Common Etiopathogenetic Mechanism?. Blood, 2013, 122, 2612-2612.	1.4	0
275	LGL Disorders: From An Inflammatory-Mediated To a Self-Maintaining Proliferation. Blood, 2013, 122, 4889-4889.	1.4	0
276	Alveolar macrophages in HIV-1 infection express accessory molecules, activation markers, and release increased biological response modifiers. Chest, 1993, 103, 108S-111.	0.8	0
277	Cellular immunity in sarcoidosis and hypersensitivity pneumonitis. Recent advances. Chest, 1993, 103, 139S-143.	0.8	0
278	Expression and functional role of tumor necrosis factor receptors on leukemic cells from patients with type B chronic lymphoproliferative disorders. Blood, 1993, 81, 752-758.	1.4	0
279	Clonal studies of CD3- lymphoproliferative disease of granular lymphocytes. Blood, 1993, 81, 2363-2368.	1.4	0
280	Feasibility and efficacy of high doses of antimetabolites followed by high-dose sequential chemoimmunotherapy (R-HDS) and autologous stem cell transplant (ASCT) in patients (pts) with systemic B-cell lymphoma (BCL) and central nervous system (CNS) involvement: A multicenter phase II trial.. Journal of Clinical Oncology, 2014, 32, 8577-8577.	1.6	0
281	Analysis of Major Infection Risk in 706 Patients with Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3321-3321.	1.4	0
282	The Atypical Gtpase Rhou Lies Downstream IL6/STAT3 and Regulates Myeloma Plasma Cells Adhesion/Motility. Blood, 2016, 128, 5661-5661.	1.4	0
283	Bortezomib, Cyclophosphamide, Dexamethasone Versus Lenalidomide, Cyclophosphamide, Dexamethasone in Multiple Myeloma Patients at First Relapse. SSRN Electronic Journal, 0, , .	0.4	0
284	Pustular eruption associated with granulocyte colony-stimulating factor treatment. Italian Journal of Dermatology and Venereology, 2018, 153, 276-277.	0.2	0
285	Insights into the Molecular Mechanism Accounting for Neutropenia in T-Large Granular Lymphocytes Leukemia. Blood, 2018, 132, 1575-1575.	1.4	0
286	Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials. Blood, 2018, 132, 2023-2023.	1.4	0
287	Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years. Blood, 2018, 132, 1688-1688.	1.4	0
288	Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study. Blood, 2019, 134, 3195-3195.	1.4	0

#	Article	IF	Citations
289	Overexpression and Targeted Activation of the Protein Phosphatases SHP-1 Abrogates Survival Pathways in Large Granular Lymphocyte Leukemia (LGLL). Blood, 2019, 134, 2798-2798.	1.4	0
290	Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability. Blood, 2019, 134, 5555-5555.	1.4	0
291	Whole Exome Sequencing Analysis in Chronic Lymphoproliferative Disorder of NK Cells (CLPD-NK) Patients Fails to Detect Significant Viral Load. Blood, 2019, 134, 5214-5214.	1.4	0
292	Ixazomib-Based Induction Followed By Single-Agent Ixazomib Maintenance in Transplant Ineligible, Newly Diagnosed Multiple Myeloma Patients: Updated Results of the EMN10-Unito Trial. Blood, 2020, 136, 27-28.	1.4	0
293	Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study. Blood, 2020, 136, 9-10.	1.4	0